Imagen de Portada

Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autor principal:	Mark J. Ratain
Formato:	Artículo Open Access
Publicado:	Wiley 2024
Materias:	Clinical Pharmacology & Therapeutics
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Therapeutic Drug Monitoring of Oral Oncology Drugs: Finding the Right Nails
por: Niels A. D. Guchelaar, et al.
Publicado: (2024)

Using Quantitative Approaches to Optimize Dosages for New Combinations and Subsequent Indications for Oncology Drugs
por: Wei Gao, et al.
Publicado: (2025)

Dosage Optimization: A Regulatory Perspective for Developing Oncology Drugs
por: Atiqur Rahman, et al.
Publicado: (2024)

Biomarkers of Drug‐Induced Kidney Injury: Use in Clinical Trials and Recent Examples of Impact on Drug Development
por: Tanja S. Zabka, et al.
Publicado: (2025)

Questioning the Design of Non‐Inferiority Trials: The Strange Case for Therapeutic Drug Monitoring Absence in Phase III Trials
por: Florian Lemaitre, et al.
Publicado: (2024)

Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and Commitments
por: Hiroe Kitagaki, et al.
Publicado: (2025)

Dose Optimization in Oncology Drug Development: An International Consortium for Innovation and Quality in Pharmaceutical Development White Paper
por: Divya Samineni, et al.
Publicado: (2024)

Phenotypic Models of Drug–Drug‐Gene Interactions Mediated by Cytochrome Drug‐Metabolizing Enzymes
por: Roberto Viviani, et al.
Publicado: (2024)

Clinical Benefit, Trials, and Regulatory Approval of Oncology Indications Under Multiple Expedited Programs for Drug Marketing in China, 2018–2024
por: Jie Zhang, et al.
Publicado: (2025)

A Comprehensive CYP2D6 Drug–Drug–Gene Interaction Network for Application in Precision Dosing and Drug Development
por: Simeon Rüdesheim, et al.
Publicado: (2025)

Impact of Model‐Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost
por: Vaishali Sahasrabudhe, et al.
Publicado: (2025)

The Persistent Ambiguity of Adverse Drug Reactions
por: Edward M. Sellers, et al.
Publicado: (2025)

Drug Interactions Brewing
por: Matthijs W. van Hoogdalem, et al.
Publicado: (2025)

Sex and the Kidney Drug‐Metabolizing Enzymes and Transporters: Are Preclinical Drug Disposition Data Translatable to Humans?
por: Aarzoo Thakur, et al.
Publicado: (2024)

New Horizons of Model Informed Drug Development in Rare Diseases Drug Development
por: Amitava Mitra, et al.
Publicado: (2024)

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
por: Cornelius Cilliers, et al.
Publicado: (2024)

Gut Microbiota in Patients with Tuberculosis Associated with Different Drug Exposures of Antituberculosis Drugs
por: Yue Zhu, et al.
Publicado: (2025)

Clinical Evaluation of Drug–Drug Interactions with Obeldesivir, an Orally Administered Antiviral Agent
por: Chi‐Chi Peng, et al.
Publicado: (2025)

Thinking Three‐Dimensionally: A Self‐ and Externally‐Controlled Approach to Screening for Drug–Drug–Drug Interactions Among High‐Risk Populations
por: Emily K. Acton, et al.
Publicado: (2024)

Reflections on Model‐Informed Drug Development
por: Lawrence J. Lesko, et al.
Publicado: (2024)

Innovations and Best Practices for Therapeutic Development in Pediatric Rare Diseases: A Model‐Informed Drug Development Perspective
por: Rajesh Krishna, et al.
Publicado: (2025)

Dose Determinations at Drug Approval Reviews: FDA‐Approved Drugs in Past 5 Years
por: Sachiko Mita, et al.
Publicado: (2025)

Chat GPT and the Challenges to Detect Potential Drug–Drug Interactions Related to QT Prolongation
por: Emanuel Raschi, et al.
Publicado: (2025)

Drug–Drug Interaction Between Dihydroartemisinin–Piperaquine and Sulfadoxine‐Pyrimethamine During Malaria Chemoprevention in Pregnant Women
por: Norah Mwebaza, et al.
Publicado: (2024)

Mechanistic Determinants of Daprodustat Drug–Drug Interactions and Pharmacokinetics in Hepatic Dysfunction and Chronic Kidney Disease: Significance of OATP1B‐CYP2C8 Interplay
por: Yi‐An Bi, et al.
Publicado: (2024)

Identifying Drug–Drug Interactions in Spontaneous Reports Utilizing Signal Detection and Biological Plausibility Aspects
por: Elpida Kontsioti, et al.
Publicado: (2024)

Phenoconversion Due to Drug–Drug Interactions in CYP2C19 Genotyped Healthy Volunteers
por: Kenza Abouir, et al.
Publicado: (2024)

Association Discovery Approach in Healthcare Big Data to Identify Drug Safety and Drug Repurposing Signals
por: George S. Q. Tan, et al.
Publicado: (2025)

Drug Critical Limits for Urgent Physician Notification
por: Elina Kuang, et al.
Publicado: (2026)

Changes in Protein Expression of Renal Drug Transporters and Drug‐Metabolizing Enzymes in Autosomal Dominant Polycystic Kidney Disease Patients
por: Annika C. Tillmann, et al.
Publicado: (2025)

Assessment of Dosing Strategies for Pediatric Drug Products
por: Zachary L. Taylor, et al.
Publicado: (2024)

The US Food and Drug Administration's Model‐Informed Drug Development Meeting Program: From Pilot to Pathway
por: Rajanikanth Madabushi, et al.
Publicado: (2024)

Drug Loss in Japan: A Comparative Analysis with Europe for New Drugs Developed by Emerging Biopharma Companies
por: Mihoko Kobayashi, et al.
Publicado: (2025)

Strategy for Identifying Rational Sensitivity Analysis Using PBPK Modeling for Precipitant Drug–Drug Interaction Predictions
por: Kunal S. Taskar, et al.
Publicado: (2025)

Emerging Tools and Technologies for Microbiome‐Aware Drug Development
por: Henry J. Haiser, et al.
Publicado: (2025)

Comprehensive Evaluation of OATP‐ and BCRP‐Mediated Drug–Drug Interactions of Methotrexate Using Physiologically‐Based Pharmacokinetic Modeling
por: Sejung Hwang, et al.
Publicado: (2024)

Zibotentan Can Be Co‐administered with Contraceptives Containing Ethinyl Estradiol and Levonorgestrel: A Pharmacokinetic Drug–Drug Interaction Study
por: Anne‐Kristina Mercier, et al.
Publicado: (2024)

New Biomarkers for Renal Transporter‐Mediated Drug–Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans
por: Arne Gessner, et al.
Publicado: (2024)

Combination Therapy With Guselkumab and Golimumab in Patients With Moderately to Severely Active Ulcerative Colitis: Pharmacokinetics, Immunogenicity and Drug–Drug Interactions
por: Jie Shao, et al.
Publicado: (2024)

Drug‐Event Pairs as Indicators for the Detection of Adverse Drug Reactions during Hospitalization in Routinely Collected Electronic Data Sources
por: Anna Maria Wermund, et al.
Publicado: (2025)